Clinical Trial Update: Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating the combination of Fruquintinib and Sintilimab, with or without radiotherapy, as third-line therapy for colorectal ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer with Liver Metastases

Drugs mentioned

• Fruquintinib (fruquintinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: Colorectal Cancer, Immunotherapy | Phase 2 | Status: RECRUITING